Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin
Abstract: Chemotherapy, which is one of the common treatments for osteosarcoma (OS), has many side effects and in some cases has low effectiveness due to chemoresistance, hence it is vital to study new therapies for OS. In this regard, we combined melatonin with cisplatin and evaluate their effect on MG63 OS cells. Since melatonin has anti-cancer properties, we hypothesized that its combination with cisplatin could increase the effectiveness of cisplatin. Firstly, MTT assay was used to evaluate the cell viability and cytotoxicity of cisplatin on MG63 cells and the results showed that melatonin in combination with cisplatin increases the sensitivity of MG63 cells to cisplatin. In addition, qRT-PCR results showed that the expressions of miR-181 and P53, CYLD, CBX7 and BCL2 genes change in MG63 cells after treatment with the combination of cisplatin and melatonin, so that the expression of P53, CYLD and CBX7 increased and the expression of BCL2 and miR-181b decreases significantly. Furthermore, analysis of Annexin V/FITC assay data revealed that the rate of apoptosis in MG63 OS cell line remarkably promoted after treated with cisplatin and melatonin combination. As a result, our findings show that melatonin in combination with cisplatin increases the effectiveness of cisplatin in osteosarcoma cells and this study provides a new therapeutic approach for OS.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin ; volume:72 ; number:06 ; year:2022 ; pages:312-318
Drug research ; 72, Heft 06 (2022), 312-318
- Contributor
-
Hosseini, Foroogh
Shanehbandi, Dariush
Soleimanpour, Jafar
Yousefi, Bahman
Alemi, Forough
- DOI
-
10.1055/a-1830-8716
- URN
-
urn:nbn:de:101:1-2022101002003332168280
- Rights
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hosseini, Foroogh
- Shanehbandi, Dariush
- Soleimanpour, Jafar
- Yousefi, Bahman
- Alemi, Forough
Other Objects (12)
Melatonin: an anti-tumor agent for osteosarcoma
Impact of limb amputation and cisplatin chemotherapy on metastatic progression in mouse models of osteosarcoma
Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin
Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
Transcriptomic analysis associated with reversal of cisplatin sensitivity in drug resistant osteosarcoma cells after a drug holiday
Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy
Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model
Cisplatin-functionalized silica nanoparticles for cancer chemotherapy
Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin
Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma
Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway
Melatonin: an anti-tumor agent for osteosarcoma
Impact of limb amputation and cisplatin chemotherapy on metastatic progression in mouse models of osteosarcoma
Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin
Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
Transcriptomic analysis associated with reversal of cisplatin sensitivity in drug resistant osteosarcoma cells after a drug holiday
Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy
Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model
Cisplatin-functionalized silica nanoparticles for cancer chemotherapy
Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin
Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma
Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway
Melatonin: an anti-tumor agent for osteosarcoma
Impact of limb amputation and cisplatin chemotherapy on metastatic progression in mouse models of osteosarcoma
Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin
Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
Transcriptomic analysis associated with reversal of cisplatin sensitivity in drug resistant osteosarcoma cells after a drug holiday
Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy
Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model
Cisplatin-functionalized silica nanoparticles for cancer chemotherapy
Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin
Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma